Company intelligence / Profile preview

InnovStone Therapeutics

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

InnovStone Therapeutics is a clinical-stage biotechnology company focused on developing next-generation cancer immunotherapies and targeted biologics. The company leverages its proprietary platforms to design innovative antibody-based therapies, including bispecific antibodies and immune-stimulating antibody conjugates (ISACs). Its lead programs target high-value oncology markers such as Claudin 18.2 and PD-L1, aiming to address unmet needs in solid tumors and hematological malignancies. Headquartered in Shanghai, InnovStone integrates research, development, and manufacturing capabilities to accelerate the delivery of precision medicines to patients globally.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugate
Industry: Biotech

Beyond the preview

Go deeper on InnovStone Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InnovStone Therapeutics.

Explore the full profile